Organisation paid for research Program year 2025 Source: CMS Open Payments

St. Louis University

Neither a doctor nor a teaching hospital

Research payments

$1,644,899

167 payments

Through program year 2025, St. Louis University is reported as receiving $1,644,899 in research payments, across 167 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$65,961	16
2024	Research	$500,653	67
2023	Research	$125,156	14
2022	Research	$673,271	20
2021	Research	$129,326	23
2020	Research	$119,005	16
2019	Research	$31,527	11

Breakdown

Who paid Research payments · program years 2019–2025

Emergent BioSolutions Inc. $645,971 4 payments
ABK Biomedical USA, Inc. $323,940 59 payments
Vertex Pharmaceuticals Incorporated $278,935 11 payments
Cardiovascular Systems Inc. $155,375 55 payments
Terumo Medical Corporation $41,214 5 payments
Mitsubishi Tanabe Pharma America, Inc. $31,303 1 payment
Aurinia Pharma U.S., Inc. $20,653 3 payments
Next Science LLC $20,400 6 payments
Abbott Laboratories $20,285 4 payments
Mitsubishi Tanabe Pharma Development America, Inc. $19,990 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $612,788 2 payments
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) $323,940 59 payments
Eclipse $175,659 59 payments
Characterizing the Relationship Between Liver Fibrosis and its Progression Assessed by Biopsy and Plasma Biomarkers of Inflammation and Elastin Turnover in PiZZ Patients with AAT Deficiency $145,000 1 payment
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury $51,293 2 payments
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $46,065 3 payments
Ravi $41,214 5 payments
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del $25,967 1 payment
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis $23,279 1 payment
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $21,183 1 payment

What the money was spent on Research payments · program years 2019–2025

Patient care $175,659 59 payments
Medical research writing or publication $15,300 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.